Clinical Pipeline

Nektar Sets Nov. 12 Date for Q3 2026 Earnings and Investor Call

SAN FRANCISCO – October 29, 2026 -- Nektar Therapeutics (Nasdaq: NKTR) will report third-quarter 2026 financial results for the period ended September 30 on Thursday, November 12, 2026, after U.S. markets close.

CEO Howard Robin to host 5:00 p.m. ET results call

President and Chief Executive Officer Howard Robin will lead a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the quarter.

Lead candidate REZPEG is being evaluated in three indications

Nektar describes itself as a clinical-stage biotechnology company focused on the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata and Type 1 diabetes mellitus.

Cadrenal CEO Pham to present at Lytham Fall 2026 conference Sept. 29

Ponte Vedra – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) will put CEO Quang X. Pham in front of investors at 10:15 a.m. ET on Tuesday, September 29, 2026, with a webcast presentation at the Lytham Partners Fall 2026 Investor Conference.

Two-day virtual conference includes one-on-one investor meetings

The conference runs virtually on September 29-30, 2026. Management will hold one-on-one meetings throughout the event. Investors can arrange them through Lytham Partners or by registering for the conference. A replay of the webcast will be available after the event.

CAD-1005 holds FDA and EMA designations in heparin-induced thrombocytopenia

Cadrenal describes itself as a late-stage biopharmaceutical company focused on critical care cardiology and orphan cardiovascular conditions. Its pipeline includes CAD-1005, tecarfarin and frunexian.